(Q40528042)

English

Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity

scientific article published on September 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity (English)

1 reference

Europe PubMed Central

21 September 2017

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

Stephen S Whitehead

5

object named as

Stephen S Whitehead

1 reference

Europe PubMed Central

21 September 2017

Kathryn A. Hanley

1

object named as

Kathryn A Hanley

1 reference

Europe PubMed Central

21 September 2017

Joseph E Blaney

7

object named as

Joseph E Blaney

1 reference

Europe PubMed Central

21 September 2017

Brian R. Murphy

6

object named as

Brian R Murphy

1 reference

Europe PubMed Central

21 September 2017

Christopher T Hanson

4

object named as

Christopher T Hanson

1 reference

Europe PubMed Central

21 September 2017

author name string

Luella R Manlucu

2

1 reference

Europe PubMed Central

21 September 2017

Gracielle G Manipon

3

1 reference

Europe PubMed Central

21 September 2017

language of work or name

0 references

publication date

1 September 2004

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

22

1 reference

Europe PubMed Central

21 September 2017

25-26

1 reference

Europe PubMed Central

21 September 2017

3440-3448

1 reference

Europe PubMed Central

21 September 2017

Dengue and dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Early clinical and laboratory indicators of acute dengue illness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Hepatic dysfunction in childhood dengue infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Development of a novel mouse model for dengue virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Human xenograft models for virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.031

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2004.02.031

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40528042&oldid=1900003652"